额颞叶痴呆的超适应证用药。
Off-label medication use in frontotemporal dementia.
机构信息
Memory and Aging Center, Department of Neurology, University of California-San Francisco, San Francisco, CA 94143, USA.
出版信息
Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):128-33. doi: 10.1177/1533317509356692. Epub 2010 Feb 1.
OBJECTIVE
There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics.
METHODS
Medication and demographic data from the Alzheimer's Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer's disease (AD), and effects of demographic variables were assessed using logistic regression.
RESULTS
Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups.
CONCLUSIONS
Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.
目的
目前尚无获得食品和药物管理局（FDA）批准的药物可用于治疗额颞叶痴呆（FTD）。我们旨在确定在专门的痴呆症诊所中治疗行为变异型额颞叶痴呆（bvFTD）最常用的药物。
方法
比较了加利福尼亚州阿尔茨海默病研究中心（ARCC）和多中心额颞叶痴呆自然史研究（NHS）数据集的药物和人口统计学数据在 bvFTD 和阿尔茨海默病（AD）中的应用，并使用逻辑回归评估了人口统计学变量的影响。
结果
总体而言，服用一种或多种 FDA 批准的 AD 或精神药物的患者百分比在 bvFTD 和 AD 中相似；然而，在控制人口统计学变量后，乙酰胆碱酯酶抑制剂（AChI）的使用在 bvFTD 中较少，而在 2 组中，美金刚的使用仍相似。
结论
尽管缺乏疗效证据，但 AChIs 和美金刚在 bvFTD 中的使用很常见。应开展临床试验，以确定 bvFTD 的最佳治疗干预措施。
Zotero 插件